Futura Medical - Asset Resilience Ratio

Latest as of December 2020: 23.08%

Futura Medical (FUM) has an Asset Resilience Ratio of 23.08% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Futura Medical (FUM) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX373.87K

≈ $45.49 USD Cash + Short-term Investments

Total Assets

GBX1.62 Million

≈ $197.12 USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2020)

This chart shows how Futura Medical's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Futura Medical balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Futura Medical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Futura Medical total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX373.87K	23.08%
Total Liquid Assets	GBX373.87K	23.08%

Asset Resilience Insights

Good Liquidity Position: Futura Medical maintains a healthy 23.08% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Futura Medical Industry Peers by Asset Resilience Ratio

Compare Futura Medical's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Futura Medical (2016–2020)

The table below shows the annual Asset Resilience Ratio data for Futura Medical.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2020-12-31	23.08%	GBX373.87K ≈ $45.49	GBX1.62 Million ≈ $197.12	+15.47pp
2019-12-31	7.61%	GBX372.90K ≈ $45.37	GBX4.90 Million ≈ $596.33	-24.12pp
2018-12-31	31.73%	GBX3.45 Million ≈ $419.94	GBX10.88 Million ≈ $1.32K	-53.58pp
2017-12-31	85.31%	GBX8.19 Million ≈ $996.95	GBX9.60 Million ≈ $1.17K	-5.51pp
2016-12-31	90.82%	GBX12.21 Million ≈ $1.49K	GBX13.44 Million ≈ $1.64K	--

pp = percentage points

About Futura Medical

LSE:FUM UK Biotechnology

Market Cap

$14.15K

GBX116.27 Million GBX

Market Cap Rank

#31794 Global

#1288 in UK

Share Price

GBX0.20

Change (1 day)

-4.76%

52-Week Range

GBX0.20 - GBX3.90

All Time High

GBX84.52